3,6-二氯-1,2,4-三嗪 | 99584-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 中文名称: 3,6-二氯-1,2,4-三嗪
• 英文名称: 3,6-dichloro-1,2,4-triazine
• CAS: 99584-48-2
• 化学式: C₃HCl₂N₃
• mdl: MFCD22548154
• 分子量: 149.967
• InChiKey: DHFJTUKAWMNXNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,6-二氯-1,2,4-三嗪 、 endo-3-Boc-aminotropane 在 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以69.1%的产率得到tert-butyl ((1R,3s,5S)-8-(6-chloro-1,2,4-triazin-3-yl)-8-azabicyclo[3.2.1]octan-3-yl)carbamate
  参考文献：
  名称：

  WO2020201991A5

  摘要：

  公开号：

  WO2020201991A5

文献信息

• WO2020163405A5
  申请人：——

  公开号：WO2020163405A5

  公开（公告）日：2023-02-13
• Nicotinic acids: Liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy
  作者：David A. Powell、W. Cameron Black、Kelly Bleasby、Chi-Chung Chan、Denis Deschenes、Marc Gagnon、Rob Gordon、Jocelyne Guay、Sebastien Guiral、Michael J. Hafey、Zheng Huang、Elise Isabel、Yves Leblanc、Angela Styhler、Li-Jing Xu、Lei Zhang、Renata M. Oballa

  DOI：10.1016/j.bmcl.2011.10.040

  日期：2011.12

  An in vitro screening protocol was used to transform a systemically-distributed SCD inhibitor into a liver-targeted compound. Incorporation of a key nicotinic acid moiety enables molecular recognition by OATP transporters, as demonstrated by uptake studies in transfected cell lines, and likely serves as a critical component of the observed liver-targeted tissue distribution profile. Preclinical anti-diabetic oGTT efficacy is demonstrated with nicotinic acid-based, liver-targeting SCD inhibitor 10, and studies with a close-structural analog devoid of SCD1 activity, suggest this efficacy is a result of on-target activity. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] SHP2 INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR DE SHP2 ET SON UTILISATION<br/>[KO] SHP2 억제제 및 이의 용도
  申请人：[en]KANAPH THERAPEUTICS INC.;[ko]주식회사 카나프테라퓨틱스

  公开号：WO2023282702A1

  公开（公告）日：2023-01-12

  SHP2의 저해제, 이를 포함하는 SHP2와 관련된 질환의 예방 또는 치료용 약학적 조성물, 이를 이용한 질병의 치료 및 예방 방법, 및 이의 용도를 제공한다. 이에 의하면, SHP2와 관련된 질환을 효과적으로 예방 또는 치료할 수 있다.
• WO2020201991A5
  申请人：——

  公开号：WO2020201991A5

  公开（公告）日：2022-09-02